作为治疗神经退行性疾病的新型治疗,SERCA是一种新的治疗
Russell Dahl1, Ilya Bezprozvanny2
1Neurodon Corporation, 9800 Connecticut Drive, Crown Point, IN, 46307, USA.
Biochemical and biophysical research communications
|September 28, 2024
概括
积极的全调节器 (PAMs) 向肉质内质网膜 (SERCA) ,为阿尔茨海默氏症和帕金森症等神经退行性疾病提供了一种新的治疗策略. 临床前数据显示有希望,即将进行人体试验,以评估安全性和有效性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 神经退行性疾病,包括阿尔茨海默病 (AD) 和帕金森病 (PD),在全球范围内带来重大健康挑战,有效治疗方法有限.
- 目前的研究重点是疾病特异性标,但由于药物开发和副作用的挑战,临床进展仍然有限.
- (Ca2+) 信号与神经退行有关,但向Ca2+通道受到外围副作用的阻碍.
研究的目的:
- 探索对神经退行性疾病的肉质内质网膜 (SERCA) 的正调节器 (PAM) 的治疗潜力.
- 审查支持SERCA调制作为可行的治疗策略的临床前证据.
- 强调即将进行的第一阶段临床试验是评估这种新方法的关键步骤.
主要方法:
- 关于神经退行性疾病病原和信号传递的现有科学文献的综述.
- 从阿尔茨海默病和帕金森病的动物模型中分析临床前数据.
- 对萨尔科内质网膜 (SERCA) 正调节器 (PAMs) 作用机制的讨论.
主要成果:
- 在AD和PD的动物模型中进行的临床前研究表明,调节SERCA活动可能是有益的.
- 塞尔卡的正调节器 (PAM) 代表了一类潜在的新疗法.
- 已识别的PAMs提供了一种有前途的方法,用于针对神经退行性疾病中的调节障碍.
结论:
- 肉质内网 (SERCA) 的正调节器 (PAM) 是神经退行性疾病的有希望的治疗途径.
- 进一步的研究,包括即将进行的第一阶段临床试验,对于验证这些化合物在人类中的安全性和有效性至关重要.
- 这种方法可以克服与先前试图针对神经退行性疾病中的信号传导相关的局限性.
相关概念视频
01:15Parkinson's Disease: Overview
492
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
492
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
01:24Parkinson's Disease: Treatment
233
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
233